Scientists funded by the National Institutes of Health (NIH) have successfully treated monkeys several days after the animals were infected with Sudan ebolavirus (SUDV). The study is important, according to the researchers, because no proven treatments against SUDV exist and little is known about the window of opportunity for treating the infection.
Scientists identified SUDV and Zaire ebolavirus (EBOV) in 1976, but EBOV has been the more common cause of outbreaks and has been the focus of nearly all treatment and vaccine research. When an EBOV variant swept through West Africa in 2014-15, physicians treated patients with several experimental therapies but it is unknown whether any of those products would be effective against SUDV.
With that need in mind, scientists at the University of Texas Medical Branch (UTMB) tested a new antiviral drug delivered intravenously to rhesus macaques using a lipid nanoparticle platform (LNP) developed by Arbutus Biopharma, based in British Columbia. The RNA-based therapeutic, called a "small-interfering RNA (siRNA)," can target specific genes to prevent viruses from replicating and may offer advantages compared to other medical countermeasures. The LNP delivery system encapsulates the drug, can increase its potency, and allows the bloodstream to deliver the drug to targeted tissues.
As part of the study, funded by NIH's National Institute of Allergy and Infectious Diseases, the UTMB group compared 48 different RNA-based drug formulations. They determined that the most effective formulation prevented replication of SUDV viral protein 35. They subsequently tested this formulation in six macaques given a lethal SUDV dose. Though all animals showed signs of disease, all six macaques recovered after receiving the siRNA-LNP treatment within four days of infection. Two of four animals survived when treated five days after infection.
The researchers are continuing their investigation of siRNA-LNP therapeutics to determine whether the approach could be effective against additional types of Ebola viruses and other hemorrhagic fever viruses.
E Thi et al. Rescue of nonhuman primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nature Microbiology DOI: 10.1038/NMICROBIOL.2016.142 (2016).
Tina M. Parker, DVM, MScPH, of NIAID's Office of Biodefense, Research Resources and Translational Research, is available to comment on this study.
To schedule interviews, please contact Ken Pekoc, 301-402-1663, firstname.lastname@example.org.
This research was supported by the following NIH grants: U19AI109711 and UC7AI094660.
NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.